An improved method for constructing tissue microarrays from prostate needle biopsy specimens
Authors:
Open Access
- 28 July 2009
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 62 (8) , 694-698
Abstract
Background: Prostate cancer diagnosis is routinely made by the histopathological examination of formalin fixed needle biopsy specimens. Frequently this is the only cancer tissue available from the patient for the analysis of diagnostic and prognostic biomarkers. There is, therefore, an urgent need for methods that allow the high-throughput analysis of these biopsy samples using immunohistochemical (IHC) markers and fluorescence in situ hybridisation (FISH) analysis based markers.Methods: A method that allows the construction of tissue microarrays (TMAs) from diagnostic prostate needle biopsy cores has previously been reported. However, the technique only allows the production of low-density biopsy TMAs with a maximum of 20 cores per TMA. Here two methods are presented that allow the rapid and uniform production of biopsy TMAs containing between 54 and 72 biopsy cores. IHC and FISH techniques were used to detect biomarker status.Results: Biopsy TMAs were constructed from prostate needle biopsy specimens taken from 102 patients entered into an active surveillance trial and 201 patients in a radiotherapy trial. The detection rate for cancer in slices of these biopsy TMAs was 66% and 79% respectively. Slices of a biopsy TMA prepared from biopsies from active surveillance patients were used to detect multiple IHC markers and to scoreTMPRSS2-ERGfusion status in a FISH-based assay.Conclusions: The construction of biopsy TMAs provides an effective method for the multiplex analysis of IHC and FISH markers and for their assessment as prognostic biomarkers in the context of clinical trials.Keywords
This publication has 15 references indexed in Scilit:
- Integration of ERG gene mapping and gene‐expression profiling identifies distinct categories of human prostate cancerBJU International, 2009
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone DrivenJournal of Clinical Oncology, 2008
- Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillanceProstate Cancer and Prostatic Diseases, 2008
- Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort studyThe Lancet Oncology, 2008
- Complex patterns of ETS gene alteration arise during cancer development in the human prostateOncogene, 2007
- Bcl-2 and Bax Expression Predict Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy on Radiation Therapy Oncology Group Protocol 92-02Clinical Cancer Research, 2007
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005
- MDM2 as a predictor of prostate carcinoma outcomeCancer, 2005
- Molecular markers of prostate cancer outcomeEuropean Journal of Cancer, 2005
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998